13F Data
13F filer · CIK 1667082

Biomark Capital Management Co. LLC

GREENWICH, CT · filing since Q4 2015 · last filing Oct 24, 2018
Reported value
$77.9M
+$5.2M vs prior
Positions
3
New / sold out
0 / 0
Added / reduced
1 / 0
Turnover
0.0%
buys $18.7M · sells $0
Top-10 weight
100.0%

Biggest buys vs Q1 2016

ChangeSecurityShares changeChange %Est. trade value
AddedJUNO THERAPEUTICS, INC.+603,364+37.6%+$18.7M

Biggest sells vs Q1 2016

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2015: $82.2MQ1 2016: $72.8MQ2 2016: $77.9MQ3 2016: $75.6MQ4 2016: $48.3MQ1 2017: $55.2MQ2 2017: $61.1MQ3 2017: $88.1MQ4 2017: $89.8MQ1 2018: $6.6MQ2 2018: $6.5MQ3 2018: $8.9M
Q4 2015Q3 2018

Holdings · Q2 2016

#SecuritySharesValueWeight
1JUNO THERAPEUTICS, INC.COMMON STOCK2,205,926$68.5M87.91%
2ADMA BIOLOGICS, INC.COMMON STOCK1,433,304$9.3M11.94%
3MABVAX THERAPEUTICS HOLDINGS, INC.COMMON STOCK197,641$119.0K0.15%